315,018 Shares in Bioventus Inc. $BVS Purchased by Engine Capital Management LP

Engine Capital Management LP acquired a new stake in shares of Bioventus Inc. (NASDAQ:BVS) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 315,018 shares of the company’s stock, valued at approximately $2,876,000. Bioventus comprises about 0.3% of Engine Capital Management LP’s investment portfolio, making the stock its 22nd biggest position.

A number of other institutional investors and hedge funds have also bought and sold shares of BVS. Caitong International Asset Management Co. Ltd raised its holdings in Bioventus by 17,156.2% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock worth $41,000 after buying an additional 5,490 shares during the last quarter. Prelude Capital Management LLC bought a new position in shares of Bioventus in the third quarter worth approximately $74,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Bioventus during the third quarter valued at approximately $78,000. SG Americas Securities LLC purchased a new stake in shares of Bioventus during the fourth quarter valued at approximately $80,000. Finally, Brooklyn Investment Group bought a new stake in shares of Bioventus during the fourth quarter valued at approximately $91,000. 62.94% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

BVS has been the subject of a number of recent analyst reports. Barrington Research restated an “outperform” rating and issued a $14.00 price objective on shares of Bioventus in a report on Tuesday, June 30th. Canaccord Genuity Group reiterated a “buy” rating and set a $15.00 target price on shares of Bioventus in a research note on Tuesday, June 16th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Bioventus in a report on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $14.75.

Bioventus Trading Up 5.5%

Shares of BVS stock opened at $12.45 on Tuesday. The company has a current ratio of 1.69, a quick ratio of 1.13 and a debt-to-equity ratio of 1.08. Bioventus Inc. has a 12-month low of $5.81 and a 12-month high of $12.53. The stock has a market capitalization of $1.04 billion, a P/E ratio of 30.37, a P/E/G ratio of 1.50 and a beta of 0.65. The firm’s 50 day moving average is $10.05 and its 200 day moving average is $9.33.

Bioventus (NASDAQ:BVS) last announced its earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.06. The business had revenue of $132.09 million during the quarter. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Research analysts expect that Bioventus Inc. will post 0.79 earnings per share for the current year.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.